Veea Inc. announced the signing of a non-binding term sheet for a proposed business combination with NovaGen Group B.V., a personalized regenerative medicine company. The potential merger aims to launch NovaGen Health Networks, a global health platform integrating Veea’s edge AI technology with NovaGen's clinical services, with an estimated combined company valuation of approximately $750 million.
Key Details
- Agreement: On September 14, 2026, Veea signed a non-binding term sheet for a business combination with Amsterdam-based NovaGen Group.
- Valuation & Investment: The combined entity is valued at approximately $750 million. As part of the transaction, cornerstone investor GeoNova Capital has committed to a $10 million investment.
- Strategic Initiative: The merger is intended to launch NovaGen Health Networks, an AI-powered platform combining Veea's edge computing and cybersecurity with NovaGen's cellular science. Initial deployments are targeted for Q4 2026.
- Contingencies: The transaction is subject to the execution of a definitive agreement, completion of due diligence, and shareholder and regulatory approvals. There is no assurance the deal will be finalized.